Industry news

FDA proposes studies on deceptive ads to gauge doc and patient perceptiveness

Beth Snyder Bulik / FiercePharmaMarketing

Can doctors and patients suss out misleading information in drug ads? That’s what the FDA wants to find out. In a proposed pair of studies, the agency will look at healthcare providers' and patients' responses to determine their ability to detect different levels and types of deception.

19 January 2017

Globally, 2016 was a bullish year for investment in the startup ecosystem with venture investment at its highest level in five years - CrunchBase

CrunchBase

The new year is upon us, and it’s a great time to set out on the right foot by incorporating data into decision-making and business strategy. Crunchbase has access to all data around the innovation economy, and we’re illuminating the trends from 2016 – and what to look out for in 2017 in "The Global Innovation Investment Report-2016".

More than half of trial researchers have financial links to biopharma

Ben Adams / Fierce Biotech

When there are financial ties between researchers working on a clinical study and the drug industry, the data from these tests are more likely to be positive, according to a new report in The BMJ, as more than half of principal investigators were found to have been given money by biopharma

Where the money is, 2016 edition: The top 100 VCs investing in biotech, by the numbers

John Carroll / Endpoints News

Using the latest set of numbers on the top 100 VCs operating in the US, you can sketch out all of the big trends at play in the multibillion-dollar game of biotech investing and startups. this is a good place to get started on that exercise.

The top 15 best-selling cancer drugs in 2022

Phil Taylor / Fierce Pharma

If there was any doubt that the oncology market is set to reach unprecedented heights, FiercePharma's top 15 list of cancer drugs in 2022 should eliminate it.

Significant progress fighting cancer: Death rate has dropped 25 percent

Holly Campbell / PhRMA

Cancers have long been one of the most devastating and complex disease areas facing patients. But thanks in part to innovative advancements in treatments and early detection, the cancer death rate in the United States has dropped 25 percent over the last two decades.

Cancer in 2016

AACR Cancer Progress Report

In th​e United States, the overall cancer death rate is decreasing, and the number of cancer survivors is increasing.​ The reduction in the U.S. cancer death rate from 1991 to 2012 translates into 1.7 million cancer deaths avoided. In 2016, 595,690 people are expected to die from some form of cancer in the United States, making it the second most common cause of death. Not all segments of the U.S. population benefit equally from advances against cancer. The cost of cancer is enormous, both in the United States and globally.

This year’s JPM roundup: deals, lack of deals, a different breed of startup, and a Trump card

Ben Adams / Fierce Biotech

The J.P. Morgan event is known as the event for biotech and the investor community and, although typically aimed at generalists, bio journalists are always on the lookout for deals, critical updates, and using the conference as a litmus test for what the year ahead may bring.

Cell therapy gets official green light for use in Russia

TASS

The law on biomedical cellular products which comes into force on January 1 permits the use of living cells for therapy and kicks off the creation of a new branch of biomedicine

Pharmaceutical and Medical Devices Market in Russia: Trends and Developments

Dmitri Nikiforov Anna Maximenko and Elena Klutchareva / CEE Legal Matters

In 2015-2016 the main trends and developments in the Russian pharmaceutical market were: (i) the establishment of the common pharmaceutical and medical devices (MDs) market of the Eurasian Economic Union (the “EEU”), (ii) the development of best practices in the pharmaceutical market through self-regulation, and (iii) preferences for pharmaceuticals and MDs of EEU origin.